BAAM
ARQT icon

Baker Avenue Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Baker Avenue Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-26
Closed -$248 – 1597
2023
Q2 		$248 Buy
+26
New +$289 ﹤0.01% 1545

Other funds holding ARQT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Baker Avenue Asset Management's ARQT Position: Q3 2023 in Review

Baker Avenue Asset Management sold out of Arcutis Biotherapeutics (ARQT) in Q3 2023, closing a stake of 26 shares — an estimated $248 sold.

Baker Avenue Asset Management first reported a position in ARQT in Q2 2023 and held it in 1 quarter. The position peaked at $248 in Q2 2023. 134 funds tracked by Wall St. Rank hold ARQT as of Q3 2023.

  • Baker Avenue Asset Management reported no remaining Arcutis Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 26 Arcutis Biotherapeutics shares in Q3 2023, an estimated $248.
  • Baker Avenue Asset Management first reported a position in Arcutis Biotherapeutics in Q2 2023 and held it in 1 quarter.
  • Baker Avenue Asset Management's Arcutis Biotherapeutics position peaked at $248 in Q2 2023.
  • 134 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2023.

Based on Baker Avenue Asset Management's 13F filing for Q3 2023, filed 15 Nov 2023.